CHPA Requests Extension To Childproof Imidazoline Product Packaging
This article was originally published in The Tan Sheet
Executive Summary
The OTC trade group says firms need two years, twice the time CPSC would allow under a proposed rule, to require child-resistant packaging for drugs with more than 0.08 mg of imidazolines, including such OTCs as Visine eye drops and Afrin nasal decongestants.
You may also be interested in...
Imidazoline Childproof Packaging Deadline Extended Six Months, Potentially More
The Consumer Product Safety Commission followed its staff’s recommendation to extend the deadline for six months, through May 10, 2105, and to consider requests for additional six-month extensions on a case-by-case basis.
Imidazoline Childproof Packaging Deadline Extended Six Months, Potentially More
The Consumer Product Safety Commission followed its staff’s recommendation to extend the deadline for six months, through May 10, 2105, and to consider requests for additional six-month extensions on a case-by-case basis.
In Brief
Imidazoline childproof package deadline extended; FDA wants to define food allergen thresholds; Danone cuts workforce in Europe; Primatene Mist bill voted down in the house; CARU urges WhoNu? ad off kids TV; Bayer recalls Bronkaid; Tate & Lyle to develop Nandi Proteins food ingredient; more news In Brief.